SAVE THE DATE! **Immunosuppression in Liver Transplantation**

ILTS Consensus and Guidance Conference | Feb. 9 and 10, 2017 | Park City, UT

**Course Directors: Josh Levitsky and Michael Charlton**

This conference will provide a detailed overview of the current challenges and advances in immunosuppressive therapy in the field of liver transplantation. International experts will convene to focus on immunosuppression management strategies and best practices in the consensus conference format. The consensus conference proceedings will be used to generate a practice guidelines manuscript for publication in *Transplantation*, official journal of the ILTS since 2015.

The conference will focus on three separate areas:

- Mechanisms, and pharmacology of immunosuppressive agents used in liver transplant recipients
- Management of adverse effects of immunosuppressive agents used in liver transplant recipients, including:
  - Viral hepatitis
  - Recurrence of nonviral primary liver disease
  - Renal toxicity
  - Malignancy
  - Metabolic syndrome
- Review emerging issues, including advances in biomarkers, pharmacogenomics and approaches to early and immunosuppression minimization.

The overall goal of this course is to discuss the past, present and future of immunosuppression therapy following liver transplantation. It will focus on the most recent advances and discuss selection of therapies based on diverse patient phenotypes.

**Learning objectives:**

- Understand the pros and cons of the use of different maintenance and induction agents
- Understand immunosuppression management strategies in special populations and disease states
- Learn the utility of therapeutic drug monitoring, drug interactions and the potential for tailored dosing based on genotypic/phenotypic patterns
- Learn about approaches to minimize the impact of long term immunosuppression, including tailoring treatments (including withdrawal) based on clinical features and immune monitoring